Special Issue "Modulation of Antibiotics and Anticancer Drugs Activity by Biocompatible Nanoparticles"
Deadline for manuscript submissions: 31 December 2020.
Interests: nanoparticles; drug activity; biologically active compounds; DNA binding; thermodynamical models; anticancer drugs; non-covalent interactions
Interests: nanoparticles; anticancer drugs; non-covalent interactions; thermodynamical models; computer simulation
Interests: drug–nanoparticle interactions; thermodynamics of binding; models of binding; aggregation
Nowadays, the treatment of many common diseases is based on drug therapy. Commonly used classical antibiotics are still less and less effective because of the emergence of new drug-resistant bacterial strains. The development of new antibiotics is decreasing each year. Therefore, it has become very important to seek new approaches in the usage of existing classic antibiotics, to give them a second life.
On the other hand, anticancer drugs commonly used in chemotherapy are effective against cancer; however, they have many adverse side effects.
Therefore, the modulation of these drugs’ activity by biocompatible nanoparticles seems to be an interesting way to improve these drugs’ activity and decrease their possible side-effects. Biocompatible nanoparticles of various natures may act as drug carriers, modify cell membrane permeability, directly interact with drug molecules, modify drug biological activity, etc. Finally, all these effects or interactions may modulate these drugs’ activity and be used successfully in treatment in the near future.
The Special Issue will cover but will not be limited to the following topics:
- The direct interaction between drugs and biocompatible nanoparticles;
- Biocompatible nanoparticles as drug carriers;
- Anticancer nanoparticle–drug effect in vitro and in vivo;
- Improving classic antibiotics’ activity by biocompatible nanoparticles.
Prof. Jacek Piosik
Prof. Yuriy Prylutskyy
Prof. Maxim Evstigneev
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Antineoplastic drugs
- Drug activity modulation
- Non-covalent interactions
- Drug side effects
- Drug resistance
- Drug efficacy
- Drug therapy